Overview

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy

Status:
Recruiting
Trial end date:
2025-01-14
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals